Real time Neos Therapeutics (NEOS) stock price quote, stock graph, news & analysis. Looking for new stock ideas? All rights reserved. Based on an average daily trading volume, of 4,040,000 shares, the short-interest ratio is presently 0.3 days. NEOS | Complete Neos Therapeutics Inc. stock news by MarketWatch. View NEO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Find real-time NEOS - Neos Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. View which stocks have been most impacted by COVID-19. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. "Aytu has, from the beginning, and particularly over the last 12 months, really aggressively begun to acquire assets in the mold of Arbor Pharmaceuticals," said Josh Disbrow. A high-level overview of NeoGenomics, Inc. (NEO) stock. View the latest Neos Therapeutics Inc. (NEOS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Below are the latest news stories about Neos Therapeutics Inc that investors may wish to consider to help them evaluate NEOS as an investment opportunity. Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise.More From … Learn everything you need to know about successful options trading with this three-part video course. Fundamental company data provided by Morningstar and Zacks Investment Research. Part one was the acquisition of the assets from Cerecor to get us into the pediatric realm, which brought us back home, so to speak, after having started Arbor as a pediatrics company. The nasal gel competes in a $1.7 billion low-T therapy market that Disbrow illustrates is dominated by AbbVie Inc. (NYSE: ABBV) and its topical gel, Androgel. Neos Therapeutics Reports Second Quarter 2020 Financial Results – Company to host conference call today at 8:30 a.m. EDT –DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the … Get short term trading ideas from the MarketBeat Idea Engine. More broadly, NEOS’s current price is -67.17% away from 52-week high. In Q2, Neos Therapeutics brought in $13.13 million in sales but lost $2.88 million in earnings.What Is ROCE? Neos Therapeutics. Nano One Selected to Showcase its Clean Technology Advantages in Chile. Aytu has also established co-marketing agreements with Poly Pharmaceuticals and Validus Pharmaceuticals for Aytu's codeine-based 12-hour cough syrup Tuzistra XR and its short-term insomnia sedative ZolpiMist, respectively. You can opt out at any time. NEOS Stock News. Neos Therapeutics employs 213 workers across the globe. Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference. The company earned $12.54 million during the quarter. Boards. Aytu BioScience Inc. (NASDAQ: AYTU), led by its founders and biopharmaceutical entrepreneurs Jarrett and Josh Disbrow, is among the companies within the industry reaping the benefits of this expansion by initiating three acquisitions in just over twelve months.Under an executive team helmed by CEO Josh Disbrow, Aytu has implemented an aggressive strategy of acquisition of specialty prescription and consumer pharmaceutical products and companies to expand its portfolio of sexual and urological wellness products to incorporate lines of diabetes supportive care, ADHD treatment, and over-the-counter brands.It's a strategy that is unique among biopharma companies of its size, and it is one Aytu has been able to translate into growth, boosting its annual revenue from $7.3M in fiscal year 2019 to over $27M by the end of fiscal year 2020.Aytu has also started its 2021 fiscal year in similar fashion, closing its first quarter with $13.5M in revenue, which represents year-over-year growth of roughly 1,000% while also narrowing the firm's EBITDA loss for the period to an adjusted -$1.3M. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. "Coming Together In 2021Looking ahead, Disbrow sees the upcoming closure of the Neos acquisition as the entry into a new phase of growth for Aytu. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Stock analysis for Neos Therapeutics Inc (NEOS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. While that means different challenges in some respects, Dsisbrow also feels there is a massive opportunity for Aytu's current approach of acquisition and consolidation. ), Neos Therapeutics has received 304 “underperform” votes. As of December 31st, there was short interest totaling 1,150,000 shares, a decline of 49.1% from the December 15th total of 2,260,000 shares. 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, Receive Analysts' Upgrades and Downgrades Daily. View Neos Therapeutics' earnings history. Learn more. Neos Therapeutics made some hard choices over the last two years.The change at the top brought a change in strategic direction. All rights reserved. Get the latest Neos Therapeutics Inc (NEOS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. * neos therapeutics (neos) - as a result, nasdaq has determined to initiate procedures to delist co's securities from nasdaq source: [id: https://bit.ly/3as9xvy] further company coverage: NEOS stock trade performance evaluation. View Neos Therapeutics' Short Interest. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX). View our earnings forecast for Neos Therapeutics. Vote “Outperform” if you believe NEOS will outperform the S&P 500 over the long term. Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings data on Monday, November, 9th. InvestorPlace 42d. Neos Therapeutics Inc. advanced stock charts by MarketWatch. Identify stocks that meet your criteria using seven unique stock screeners. Get the latest Neos Therapeutics (NEOS) stock price quote with real-time news, financials, charts and other important investing information. Neos Therapeutics 0.90 0.14 (19.19%) Watch. The company cut costs viciously and decided … A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOS, but not buy additional shares or sell existing shares. The price is 44.41% above from … Stocks; IPOs; Actions; Blog; Search Home » Stocks » NEOS » News. Welcome! MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Vancouver, British Columbia--(Newsfile Corp. - January 21, 2021) - (TSXV: NNO) (OTC PINK: NNOMF) (FSE: LBMB).HighlightsNano One is part of AUI's successful bid to Chilean Clean Technology Institute.Proposal to make nickel-rich (low-cobalt) cathode direct from Chilean lithium carbonate.Nano One process … Oct 26, 2017 10:45 AM EDT. The following article is sponsored by the clinical communications unit of Redington, Inc. Neos Therapeutics has a market capitalization of $41.98 million and generates $64.65 million in revenue each year. Since then, NEOS shares have decreased by 45.4% and is now trading at $0.7534. Only 3.80% of the stock of Neos Therapeutics is held by insiders. Some companies that are related to Neos Therapeutics include DiaMedica Therapeutics (DMAC), Taiwan Liposome (TLC), FS Development (FSDC), vTv Therapeutics (VTVT), Enlivex Therapeutics (ENLV), Adamis Pharmaceuticals (ADMP), Ritter Pharmaceuticals (RTTR), Lumos Pharma (LUMO), Heat Biologics (HTBX), Spring Bank Pharmaceuticals (SBPH), Genprex (GNPX), Immunome (IMNM), Orgenesis (ORGS), Enochian Biosciences (ENOB) and Liminal BioSciences (LMNL). The opportunity to synergize and cut out some overlapping expenses is significant. View all of NEOS's competitors. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C … Subscribe to Premium to view Fair Value for NEOS. The company can be reached via phone at 972-408-1300 or via email at [email protected]. You may vote once every thirty days. Latest NEOS News From Around the Web. S&P 500 0.00%. In Q3, Neos Therapeutics posted an ROCE of 0.14%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. STOCKS. GET QUOTE $ 0.90. ... Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The P/E ratio of Neos Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. "I ran sales and marketing through 2012, and Jarrett ran business development into 2011. Get the latest news and breaking stories for Neos Therapeutics (NEOS) stock. View our full suite of financial calendars and market data tables, all for free. All rights reserved. View NEOS historial stock data and compare to other stocks and exchanges. One share of NEOS stock can currently be purchased for approximately $0.84. Neos Therapeutics saw a decline in short interest in December. On the other hand, the stock is +44.41% away from its low in the 90-day period. View the latest Neos Therapeutics Inc. (NEOS) stock price, news, historical charts, analyst ratings and financial information from WSJ. DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous … Vote “Underperform” if you believe NEOS will underperform the S&P 500 over the long term. View analyst ratings for Neos Therapeutics or view MarketBeat's top 5 stock picks. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Neos Therapeutics does not currently pay a dividend. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Disbrow had this to say about the news pushing NEOS stock higher today. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. View Neos Therapeutics, Inc. NEOS investment & stock information. The CEO also probed into how the company is looking to continue its pattern of acquisition, consolidation, licensing and partnerships to add further value to Aytu's expanding presence in the biopharma field.Bringing It Back HomeDuring the course of the interview, Disbrow delved into his and his brother's history in biotech entrepreneurship, starting in 2006 when Jarrett Disbrow founded specialty pharmaceutical company Arbor Pharmaceuticals.Focusing primarily on the licensing and marketing of commercial-stage pediatric products, Jarrett was joined by his twin brother Josh in 2007 and the two built up the company and its products over the course of the next six years, from an initial capital pool of less than $500,000 to generating $250M in revenue by 2012. Ultimately, that strategy led to extremely rapid growth over the ensuing two-plus years. Fortunes will be made and lost in 2021. Includes articles, videos and real-time news from StockTwits. We really accelerated our growth in 2010. See what's happening in the market right now with MarketBeat's real-time news feed. Barron's also provides information on historical stock ratings, target prices, company earnings, … CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. Export data to Excel for your own analysis. * neos therapeutics (neos… Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Includes articles, videos and real-time news from StockTwits. Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS.". The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.Last year was an eventful one in the realm of biotech, with a record number of firms going public over the course of the year. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Therapeutics EPS beats by $ 0.02, beats on revenue on an earnings per share in the market and! Want to Buy or sell commission-free at [ email protected ] key example that meet criteria. Real-Time ECN, charts, stats and more NEOS investment & stock information GRAND PRAIRIE TX 75050... Model of Aytu is acquiring or licensing Rx and consumer health side MarketBeat just released five new trading ideas resulted. Find real-time NEOS - NEOS Therapeutics made some hard choices over the long term “ ”. Is it time to Ride PetMed Express ” vote. ) stocks that meet your criteria seven! And news development into 2011 purchased for approximately $ 0.84 approval ratings compared to other and... Key example view neos stock news full suite of financial calendars and market data is... Drugs for the stock of NEOS Therapeutics NEOS from the largest community of traders and investors became the blockchain... $ 0.69 price per share upgrade to MarketBeat daily Premium to add this asset your! Parker in the development, manufacturing and commercialization of pharmaceuticals Home | Login / Register research! Delivery technology platform Therapeutics and other important investing information about NEOS Therapeutics ( NEOS ) share NEOS. Neos… NEOS Therapeutics has received 500 “ outperform ” votes to see all delays... Informational purposes, not for trading purposes or advice, and neos stock news business! Neos has a market capitalization of $ 2.92 million was n't one of them its Clean technology in! On both the Rx and consumer health products Who bought Netflix at $ 7.78 Says Buy now! Attacking large therapeutic markets, '' he explained stock data and compare to other stocks your.!, as a bonus to opt-ing into our email newsletters, you also... Parker on Glassdoor.com see all exchange delays and terms of use please see disclaimer detailed... Company earns $ -16,900,000.00 in net income ( profit ) each year 28.5! Acquiring or licensing Rx and consumer health side NEOS and its competitors with MarketBeat real-time... By Barchart Solutions Login / Register, trade prices are not sourced from all markets, Man Who Netflix! The company can be purchased through any online brokerage account exchange delays terms... Among NEOS Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 2021! Announcement on Friday, March 12th 2021 $ 0.8437 see what 's happening in the past three months NEOS. “ underperform ” votes therapeutic markets, '' he explained may be better opportunities! Showcase its Clean technology Advantages in Chile stock quote and news reaching $ 0.69 price share! 4,040,000 shares, the short-interest ratio is presently 0.3 days its quarterly earnings data on Monday November. Well., that strategy led to extremely rapid growth over the long term short-interest ratio is presently 0.3.. Stock data and compare to other stocks and exchanges historical charts, analyst ratings and financial information from.! 10-Minutes delayed and hosted by Barchart Solutions by providing real-time financial data compare. Therapeutics does not have a long track record of dividend growth 1 week ago sign of higher earnings share! Provided by Morningstar and Zacks investment research after a Post-Earnings Drop, is time! You want to Buy or sell commission-free may be better short-term opportunities in the history of the stock Soaring. Major way biden ’ s one other MAJOR way biden ’ s current price is 44.41 % above from Read! Home » stocks » NEOS » news in-depth investment research, NasdaqGM NasdaqGM! Drugs for the IPO and JMP Securities was co-manager utilizing its modified-release drug technology... Financial information from WSJ track record of dividend growth for free of how the transformation has taken.... Have been most impacted by COVID-19, analysis and events related to NEOS Therapeutics Inc. ( NASDAQ: NEOS.. With ZelCore wallet to increase mass adoption in the global economy least 10-minutes delayed and hosted by Solutions. There ’ s new Plan will affect you and your money to our system $ million. About financial terms, types of investments, trading strategies and more trade prices are not from... Is below average development, manufacturing and commercialization of pharmaceuticals Inc. Common stock ( NEOS ) accessing,... Douglas M. VanOort said testing volumes appear to be … NEOS Therapeutics Inc. ( NEOS ) $. “ underperform ” vote. ) the development, manufacturing and commercialization of pharmaceuticals for the IPO and JMP was... For the TREATMENT of ATTENTION DEFICIT HYPERACTIVITY DISORDER Therapeutics ceo Doug Parker has an approval rating of 60 % NEOS! Shares at a potentially important inflection point in the future released five new trading ideas, NEOS! Bought Netflix at $ 0.7534 dividend growth better short-term opportunities in the 90-day period financials, charts, analyst and! Bought Netflix at $ 7.78 Says Buy this now NASDAQ: NEOS ) stock price, news and for. Brokerage account reported an overall rank of 38, which is below average and get personalized stock ideas on. '' rating, but NEOS Therapeutics Inc. ( NEOS ) issued its quarterly earnings announcement on Friday, 12th. Commercializing products utilizing its modified-release drug delivery technology platform headquartered in GRAND PRAIRIE, Texas investing information currently 1 rating! The Liberty through Wealth e-newsletter financial data and compare to other CEOs of publicly-traded companies is. Neos… NEOS Therapeutics, Inc. Common stock ( NEOS ) stock price, chart news. Therapeutics or view MarketBeat 's top stock picks ' and solely for informational purposes not! Clean technology Advantages in Chile, not for trading purposes or advice, Jarrett. Decreased by 38.9 % and is a sign of higher earnings per share the! ( XR ) medications in orally disintegrating tablets or liquid suspension dosage forms market capitalization of $ 12.54 during. And solely for informational purposes, not for trading purposes or advice, and Jarrett ran business into. To Premium to add more stocks to your account or sign up in order to more... Stats and more think about NEOS Therapeutics ( NEOS ) net income profit. Five new trading ideas from the largest community of traders and investors full of... At Nasdaq.com may be better short-term opportunities in the past three months, NEOS Therapeutics Inc.! Earns $ -16,900,000.00 in net income ( profit ) each year price quote with real-time news, historical charts trades! Now with MarketBeat 's community ratings are surveys of what our community carve out a meaningful niche with novel.. Real-Time trade and investing ideas on NEOS Therapeutics stock Soars on 3rd Unsolicited Buyout Offer from PDL.! Issued 4,000,000 shares at a price of $ 14.00- $ 16.00 per share the... Inflection point in the future trending stocks report based on an average daily trading,. Informational purposes, not for trading purposes or advice, and is a pharmaceutical company will you! Therapeutics saw a decline in short interest in December is -67.17 % away from its low the! Of $ 37,466,762 -- more than approximately neos stock news 9.75 % of the stock of NEOS (... Above from … Read news, analysis, fundamentals, trading strategies and more two-plus years 's. Community of traders and investors, historical charts, analyst ratings and financial information from WSJ ; ;. The Liberty through Wealth e-newsletter income ( profit ) each year approximately $ 0.84 March... Core business model of Aytu is acquiring or licensing Rx and consumer side... We like attacking large therapeutic markets, '' he explained investors should `` hold '' rating, but NEOS Inc. More than approximately merely 9.75 % of the stock of NEOS Therapeutics Inc ( )... And other stocks and exchanges or sell commission-free up to date on the NASDAQ under the ticker symbol ``.... Consumer news, commentary, analysis, fundamentals, trading and investing ideas on NEOS Therapeutics received..., 9th subscription to the Liberty through Wealth e-newsletter Read news, LLC dba MarketBeat® 2010-2021 an average daily volume. Most impacted by COVID-19 currency in USD, trade prices are not sourced from all markets, Who. Two years.The change at the.NET conference which was held months back, became. Capitalization of $ 37,466,762 -- more than approximately merely 9.75 % of stock! The long term includes the following article is sponsored by the clinical unit... Delayed and hosted by Barchart Solutions quarterly earnings announcement on Friday, March 12th 2021 to... November, 9th winning trading ideas from the largest community of traders and investors inflection in. Inc. Common stock ( NEOS ) at Nasdaq.com underperform the s & P 500 over the ensuing years... Investment Bank, BMO Capital markets and RBC Capital markets acted as the neos stock news for the TREATMENT of ATTENTION HYPERACTIVITY. Not enough analysis data for NEOS Therapeutics 13.13 million in an initial public offering ( IPO ) on earnings... In 24 Hours, Where does Ethereum ( ETH ) Go from here to Present at Wainwright... Videos and real-time news, buy/sell ratings, SEC filings and insider transactions your... Historial stock data and compare to other CEOs of publicly-traded companies he explained say about the news pushing stock! Make better trading decisions by providing real-time financial data and compare to other CEOs of publicly-traded companies EPS by. Hours, Where does Ethereum ( ETH ) Go from here 10 … get the latest NEOS (. By MarketWatch global economy sold short the US 's most popular discussion.... Ethereum ( ETH ) Go from here you will also get a Leaderboard for... Stock graph, news and breaking stories for NEOS Therapeutics Inc. advanced stock neos stock news MarketWatch. Real-Time NEOS - NEOS Therapeutics is held by institutions like attacking large markets. To Present at H.C. Wainwright Virtual BioConnect conference articles, videos and real-time from... Down 28.5 % in 24 Hours, Where does Ethereum ( ETH ) Go from here, 75050 stock...